fda compounding semaglutide enforcement news november 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Semaglutide injections will no longer

Until approval is granted, no legitimate private provider or doctor can supply Retatrutide

provide substantial contribution to interpretation of data, critically reviewed the manuscript, contribute an important intellectual content and gave final approval of the manuscript

While we expect this pivot to continue to be disruptive in the short-term, we believe it will lead to long-term growth and refinement of a strategy that we could utilise out of the gate in the US market. With the new strategic direction and near-term disruption, management expects preliminary, unaudited revenue for the second quarter of 2025 to be approximately $3 million and an operating loss of approximately $7 million as compared to an operating loss of $9.3 million in the second quarter of 2024

Because glucagon receptor activation can raise blood glucose in isolation, the simultaneous GLP-1 and GIP stimulation is essential to maintaining glycaemic safety which is one reason why retatrutide must only be used under close medical supervision